Cancer Profiling Market
Cancer Profiling Market By Product (Instruments, Consumables), By Indication (Breast, Colorectal, Ovarian, Melanoma, Kidney, Lung and Rare Cancer), By End User, By Test Cancer, By Region - Global Market Insights 2021 to 2031
Analysis of Cancer Profiling market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Cancer Profiling Market Outlook
The global cancer profiling market is expected to yield significant gains across 2021, as preference for precision-based medicine and high quality oncology care acquires increasing traction. With global cancer burden slated to proliferate, patients and medical practitioners alike are scrambling to offer highly efficacious and long-lasting cancer diagnostics, prompting the entry of numerous service providers.
Key solution providers are effectively leveraging smart technology, nanomedicine, and automation to accelerate diagnostic processes. Reduction in testing timeframes to provide accurate results has helped patients seek timely treatment to mitigate their cancers. The report by Fact.MR provides a taxonomy elaborating on key market segments. It also outlines visionary insights on the dynamics of the market, including the drivers, restraints, opportunities, trends, and pricing analysis, along with key success factors. Market trends have been tracked in 20+ high-growth countries.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Historical Vs Future Growth Projections
The global cancer profiling market has experienced substantial gains during the historical period of 2016 to 2020. According to Fact.MR, the market surpassed US$ 900 million revenue in 2018, expanding at an annual growth rate of 4%. Absolute opportunity worth US$ 36 million was generated in 2019.
Past growth is primarily attributed to heightened research & development initiatives undertaken by governments, research institutions, and healthcare professionals to introduce state-of-the-art therapeutic and profiling approaches. Moreover, increasing regulatory approvals by government entities have helped augment the sales of cancer profiling tests.
For instance, in November 2017, the U.S. Food & Drug Administration authorized the Memorial Sloan Kettering Cancer Center’s Integrated Mutation Profiling of Actionable Cancer Targets (IMPACT) tumor profiling test. Such approvals are expected to rise in the future, widening the berth for upcoming sales.
How is Rising Global Cancer Burden Augmenting Demand for Cancer Profiling?
Cancer has emerged as one of the leading causes of death, and a significant impediment to growing life expectancy. The World Health Organization, in 2019, pegged it as amongst the leading causes of fatalities among people below 70 years of age. As per estimates by GLOBOCAN 2020, approximately 19.3 million new cancer cases and nearly 10 million deaths occurred in the previous year.
Female breast cancer surpassed lung cancer, recording 2.3 million new cases (12%), followed by colorectal cancer (10%), prostate (7.3%), and stomach (5.6%). Thus, it can be concluded that, the global burden of cancer incidence and mortality has surged, and will continue to increase in the long run. Thus, governments across the world are investing in extensive cancer eradication programs.
As per the American Cancer Statistics' estimates, by 2040, global burden is expected to increase to 27.5 million afflictions, with over 16 million expected fatalities. Consequently, advancements have been seen in oncology care, with demand for personalized medicine experiencing a massive incline. Hence, cancer profiling is gaining traction, with specific gene mutation identification and targeted therapies receiving credible nudge.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
What Scope Do Technological Advancements Have in Furthering Cancer Profiling?
While conventional cancer treatment therapies such as chemotherapy and radiotherapy continue to hold sway, researchers are touting more precision-based and targeted approaches to streamline the entire process. Such transformative technological impacts are prompting diagnostics providers to seek highly sophisticated cancer profiling approaches.
A major breakthrough observed in this regard is the advent of nanomedicine. In the conventional sense, nanomedicines are used to modulate biodistribution and target site accumulation of systemically administered chemotherapy drugs to strike a balance between efficacy and toxicity. Starting 2015, the US Food & Drug Administration approved Onyvide and Vyxeos, some of the first anticancer nanomedicines.
Prominent cancer profiling market players are expected to effectively leverage smart sciences to dole out advanced equipment in the future. Boehringer Ingelheim, for instance, currently offers an in-class SOS1::KRAS inhibitor BI 1701963. This is a protein-protein inhibitor that binds to the Son of sevenless homolog 1 (SOS1), one of the guanine nucleotide exchange factors switching the KRAS gene into an ‘on’ state to single cell proliferation leading to cancerous growth. In 2019, BioGenex released the NanoMtrx® 300, a compact 30-slide bench-top fully automated pathology workstation for immunohistochemistry (IHC) and in situ hybridization (ISH).
Will Burgeoning Demand for Personalized Medicine Bolster Growth?
Personalized medicine is becoming increasingly mainstream, with patients demanding more precision-based and efficacious cancer treatments. Recent advancements in genomics, computational biology, medical imaging, and diagnostic technologies are prompting practitioners to developed advanced therapeutic approaches.
Emerging oncology personalized medical treatment include the TLR9 Agonist plus Immunotherapy and the EGFR/HER2 Exon 20 Mutation therapy, respectively. The former approach uses the investigational toll-like receptor 9 (TLR 9) agonist CMP-001 in combination with pembrolizumab (Keytruda) to reverse resistance to anti-PD1 therapy, an important treatment procedure in metastatic melanoma.
In the latter case, researchers are investigating possible approaches to treat non-small cell lung cancers (NSCLC) with the introduction of new drugs for treating NSCLC associated with EGFR and HER2 exon 20 insertions or mutations.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
How is Lower Ceiling on Predictive Biomarkers Identification Restraining Growth?
As genomic instability and acquisition of mutations are the hallmarks of cancer, tumor heterogeneity continues to pose challenges for the identification, testing, and development of cancer biomarkers. These challenges are prevalent across the drug development landscape, wherein, their implementation in clinical drug trials is advancing at a staggering pace.
For these reasons, the landscape of cancer therapy seeks potential strategies for the development of robust biomarkers that complements the evolving cancer alterations, thereby enabling efficient tumor biopsies using cancer profiling. While the ongoing cancer therapeutic scenario is lagging behind in biomarker development, considerable investments are in pipeline, and their outcome is expected to aid in the progress of cancer profiling landscape in the future.
Country-wise Analysis
How Lucrative is the U.S. Cancer Profiling Market?
The United States is expected to garner significant share in the cancer profiling landscape. A study conducted by the American Cancer Society projects a substantial increase in the incidence of numerous cancers across the country in 2021. It estimates that, over 1.8 million people are expected to suffer from some or the other malignancy, with over 600 thousand deaths. Therefore, government initiatives have been undertaken to contain the spread of this debilitating disease. These include launching awareness campaigns and promoting highly advanced cancer profiling and detection research.
The National Cancer Institute has been playing a pivotal in advancing sophisticated cancer research studies and initiatives, including on cancer biology, cancer genomics, and cancer prevention. At present, the agency is working on determining the efficacy of patient derived xenograft (PDX) mice-based clinical trials. These mice largely retain the genetics of human tumors from which they were initially created. This is expected to reassure clinicians about the validity of novel cancer treatment and detection studies and approaches.
Will Biological Research Programs Drive Demand for Cancer Profiling in the U.K.?
Key cancer profiling equipment manufacturers and suppliers are increasingly penetrating the U.K. market amid heightened biological research to develop effective cancer diagnostics. Cancer Research UK reported that, since January 2021, a series of studies have been proposed to establish possible links between cancer cell growth and serine intake.
Results yielded until now have been variable, as certain cancer cells are efficient at producing their own serine, especially amongst patients with KRAS mutations. Fortunately, researchers are hopeful of obtaining a standardized conclusion through subsequent studies, thereby heightening prospects for deployment various cancer profiling approaches in the long-run.
The U.K. market is characterized by the presence of various oncology diagnosis providers such as GE Healthcare. The company offers highly advanced mammography solutions, including the Senographe PristinaTM Contrast Mammography, the Senographe Crystal NovaTM digital mammography transformation, and the SenoBrightTM HD. Moreover, players are leveraging AI-enabled solutions, such as Ibex Medical Analytics who unveiled its Galen Prostate platform in June 2020.
Why are Cancer Profiling Players Increasing Penetration across Germany?
According to Globocan 2020, total number of prevalent cancer cases across Germany amounted to over 2 million in the last five years, with over 600 thousand new cases and 252 thousand fatalities. Heavy smoking and binge drinking are attributed as key culprits behind the rising prevalence of cancer across the country.
According to the European Commission’s report, nearly one in five adults reported smoking every day in 2017, with over one-fifth of men and nearly a sixth of women reporting daily tobacco consumption. Consequently, prevalence of lung cancer has increased, with fatality rates comprising nearly 40% of the country’s population. As a result, the scope for cancer diagnosis and treatment has increased in recent years.
Robust institutional frameworks such as the German Cancer Consortium and key University Medical Center-based Comprehensive Cancer Centers (CCCs) play an instrumental role in further advanced cancer research throughout the country. Such heightened support is attracting key cancer profiling equipment manufacturers across the country.
How are Manufacturers Likely to Benefit from the Indian Market for Cancer Profiling?
India exhibits credible potential with respect to cancer profiling research. Studies of cancer genetics and medical oncology are core research fields, receiving over 30% of total research funding. Research funding for surgical oncology constitutes 9% of overall spending. Growth is also fueled by high cancer incidence, with over a million new cases being diagnosed annually.
On an average, approximately 15% of diagnosed cancer patients opt for treatment, with the rest of them remaining ignored. This disturbing trend has alerted the government, which is accelerating national level initiatives to prevent unwanted fatalities. International level collaborations are also helping bolster advanced cancer research.
In 2018, the Indian government signed a MoU with the U.K. to initiate a bilateral level cancer research initiative. The collaboration has successfully brought together medical practitioners on a single platform to address research challenges attributed to affordability, prevention, and care by improving progress against cancer outcomes. Such efforts are attracting cancer profiling manufacturers across the country.
Category-wise Insights
How is Lung Cancer Profiling Stimulating Growth?
In terms of indication, profiling for lung cancer, including non-small cell lung cancer (NSCLC), is likely to receive major tailwinds, attributed to increased prevalence across all regions. According to a paper published in the National Center for Biotechnology Information in 2019, novel, highly sensitive blood-based assays to test cfDNA and ctDNA at very low concentrations for genomic abnormalities have been developed.
Moreover, in recent times, methylation of ctDNA has emerged as a potential lung cancer diagnostic and screening testing tool. A major advantage of this testing is its remarkable stability as compared to other potential biomarkers. Furthermore, DNA methylation alteration detection happens at during early carcinogenesis, enabling clinicians to take appropriate steps to prevent further lung cancer spread.
Why is Next Generation Sequencing Highly Sought-after?
Over the years, cancer prevalence has aggrandized manifold, prompting researchers to discover novel therapeutic approaches. Hence, genomics-focused pharmacology has acquired center stage, providing major traction to next generation sequencing. Compared to conventional approaches, NGS offers greater accuracy, sensitivity and speed.
As NGS can assess multiple gains in a single assay, it eliminates the need to order multiple tests to identify the causative mutation. Furthermore, NGS testing enables mutation detections at as little as 5% of the DNA isolated from a tumor sample. This approach is expected to find applications across major types of cancers, including NSCLC, liver cancer, and breast cancer, among others.
Will FISH Cancer Profiling Instruments Provide Significant Nudge to the Market?
By product, fluorescence in-situ hybridization (FISH) instruments are anticipated to garner substantial revenue shares through the forecast period. FISH profiling is less time-consuming as compared to conventional approaches. It assists in easy chromosomal microdeletion, amplification, and translocation.
Players such as Cytocell are highly prominent in FISH instrument manufacturing. It currently offers the BAC-2-FISHTM process-based FISH probes christened as myProbes®. Likewise, ADS Biotec manufactures the CellWriterTM Workstation to produce its patented FISHArrayTM technology to allow multiple cytogenetic assay performances.
Competitive Landscape
These aforementioned players rely on a variety of organic and inorganic growth strategies to cement their market presence. Offering new products, forging strategic alliances, acquisitions and mergers with other players, and conducting clinical trials for determining drug efficacy are a few examples.
- For instance, F. Hoffmann La Roche Ltd. presented updated overall survival (OS) data from its Phase III IMbrave 150 study evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevazicumab) in comparison with sorafenib in people suffering from unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
- In January 2021, Illumina Inc. announced a series of new and expanded oncology partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck, to advance comprehensive genomic profiling. These partnerships were concluded to expand its TruSightTM Oncology 500 (TSO 500) Research Use Only comprehensive pan-cancer assay to profile known and emerging biotumors.
- Recently, February 2021, QIAGEN NV partnered with INOVIO to develop next generation sequencing (NGS) companion diagnostics for the latter’s VGX-3100 for cervical dysplasia treatment. The initial project in this expanded collaboration focuses on the co-development of a diagnostic test that identifies women who are most likely to benefit from clinical use of VGX-3100.
Report Scope
|
Attribute |
Details |
|
Forecast Period |
2021-2031 |
|
Historical Data Available for |
2016-2020 |
| Market Analysis | US$ Mn for Value & ‘000 Tests for Volume |
|
Key Regions Covered |
|
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Pricing |
Available upon Request |
Key Market Segments Covered
-
Product
- Instruments
- Immunohistochemistry (IHC) Analyzers
- Fluorescence in-situ Hybridization (FISH) Instruments
- PCR Instruments
- DNA Sequencer
- Fragment Analyzer
- Consumables
- Reagents & Kits
- Other Ancillary (Probes, Holders, etc.)
- Instruments
-
Indication
- Breast Cancer
- Colorectal Cancer
- Ovarian Cancer
- Melanoma
- Kidney Cancer
- Lung Cancer (including NSCLC)
- Rare Cancers
-
End User
- Hospitals
- Diagnostic Centers
- Cancer Research Institutes
- Others
-
Test
- Immunohistochemistry (IHC)
- Fluorescence in-situ Hybridization (FISH)
- Qualitative Polymerase Chain Reaction (qPCR)
- Next Generation Sequencing (NGS)
- Sanger Testing
- Fragment Analysis
-
Region
- North America
- Latin America
- Europe
- CIS & Russia
- Japan
- APEJ
- MEA
Table of Content
1. Executive Summary – Global Cancer Profiling Market 1.1. Market Summary 1.2. Analysis Summary 1.3. Megatrends in Cancer Profiling Market 1.4. Opportunity Assessment 1.5. Wheel of Fortune Opportunity Analysis 1.6. Fact.MR View Point 2. Market Overview 2.1. Market Introduction 2.2. Market Definition 2.3. Scope of the Report 3. Market Dynamics 3.1. Macro - Economic Factors Influencing Demand 3.2. Key Growth Drivers and Impact Analysis 3.3. Industry Challenges and Restraints 3.4. Forecast Factors and Relevance of Impact 4. Key Inclusions 4.1. Regional Pricing Analysis by Test (2020) 4.2. Cancer Epidemiology By Region, 2020 4.2. PORTER's Analysis 4.2. Cancer Profiling Regulatory Senario 5. Global Cancer Profiling Market Analysis and Forecast 5.1. Global Cancer Profiling Market Outlook 5.1.1. Market Value Analysis & Forecast 5.2. Global Cancer Profiling Market Analysis by Product Type 5.2.1. Instruments 5.2.1.1. Immunohistochemistry (IHC) Analyzers 5.2.1.2. Fluorescence In situ Hybridization (FISH) Instruments 5.2.1.3. PCR instruments 5.2.1.4. DNA Sequencer 5.2.1.5. Fragment Analyzer 5.2.2. Consumables 5.2.2.1. Reagents & Kits 5.2.2.2. Other Ancillary (probes, holders etc.) 5.2.3. Market Attractiveness Analysis by Product Type 5.3. Global Cancer Profiling Market Analysis by Indication 5.3.1. Breast Cancer 5.3.2. Colorectal Cancer 5.3.3. Ovarian Cancer 5.3.4. Melanoma 5.3.5. Kidney Cancer 5.3.6. Lung Cancer (including NSCLC) 5.3.7. Rare Cancers 5.3.8. Market Attractiveness Analysis by Indication 5.4. Global Cancer Profiling Market Analysis by End User 5.4.1. Hospitals 5.4.2. Diagnostic Centres 5.4.3. Cancer Research Institutes 5.4.4. Others 5.4.5. Market Attractiveness Analysis by End User 6. North America Cancer Profiling Market Analysis 6.1. Introduction 6.1.1. North America Cancer Profiling Market Outlook 6.2. North America Cancer Profiling Market Outlook 6.2.1. Market Value (US$ Mn) Forecast and Analysis 6.2.2. Country Wise Demand Assessment 6.2.2.1. US Market Value Share 6.2.2.2. Canada Market Value Share 6.3. North America Cancer Profiling Market Analysis by Product Type 6.3.1. Value (US$ Mn) Forecast by Product Type 6.3.2. Y-o-Y Growth Comparison by Product Type 6.4. North America Cancer Profiling Market Analysis by Indication 6.4.1. Value (US$ Mn) Forecast by Indication 6.4.2. Y-o-Y Growth Comparison by Indication 6.5. North America Cancer Profiling Market Analysis by End User 6.5.1. Value (US$ Mn) Forecast by End User 6.5.2. Y-o-Y Growth Comparison by End User 6.6. Market Attractiveness Analysis 6.7. Heat Map Analysis 6.8. Impact Assessment of Market Forces 7. Latin America Cancer Profiling Market Analysis 7.1. Introduction 7.1.1. Latin America Cancer Profiling Market Outlook 7.2. Latin America Cancer Profiling Market Outlook 7.2.1. Market Value (US$ Mn) Forecast and Analysis 7.2.2. Country Wise Demand Assessment 7.2.2.1. Brazil Market Value Share 7.2.2.2. Mexico Market Value Share 7.2.2.3. Rest of LATAM Market Value Share 7.3. Latin America Cancer Profiling Market Analysis by Product Type 7.3.1. Value (US$ Mn) Forecast by Product Type 7.3.2. Y-o-Y Growth Comparison by Product Type 7.4. Latin America Cancer Profiling Market Analysis by Indication 7.4.1. Value (US$ Mn) Forecast by Indication 7.4.2. Y-o-Y Growth Comparison by Indication 7.5. Latin America Cancer Profiling Market Analysis by End User 7.5.1. Value (US$ Mn) Forecast by End User 7.5.2. Y-o-Y Growth Comparison by End User 7.6. Market Attractiveness Analysis 7.7. Heat Map Analysis 7.8. Impact Assessment of Market Forces 8. Europe Cancer Profiling Market Analysis 8.1. Introduction 8.1.1. Europe Cancer Profiling Market Outlook 8.2. Europe Cancer Profiling Market Outlook 8.2.1. Market Value (US$ Mn) Forecast and Analysis 8.2.2. Country Wise Demand Assessment 8.2.2.1. EU -4 Market Value Share 8.2.2.2. UK Market Value Share 8.2.2.3. Benelux Market Value Share 8.2.2.4. Nordic Market Value Share 8.2.2.5. Rest of Europe Market Value Share 8.3. Europe Cancer Profiling Market Analysis by Product Type 8.3.1. Value (US$ Mn) Forecast by Product Type 8.3.2. Y-o-Y Growth Comparison by Product Type 8.4. Europe Cancer Profiling Market Analysis by Indication 8.4.1. Value (US$ Mn) Forecast by Indication 8.4.2. Y-o-Y Growth Comparison by Indication 8.5. Europe Cancer Profiling Market Analysis by End User 8.5.1. Value (US$ Mn) Forecast by End User 8.5.2. Y-o-Y Growth Comparison by End User 8.6. Market Attractiveness Analysis 8.7. Heat Map Analysis 8.8. Impact Assessment of Market Forces 9. CIS & Russia Cancer Profiling Market Analysis 9.1. Introduction 9.1.1. CIS & Russia Cancer Profiling Market Outlook 9.2. CIS & Russia Cancer Profiling Market Outlook 9.2.1. Market Value (US$ Mn) Forecast and Analysis 9.3. CIS & Russia Cancer Profiling Market Analysis by Product Type 9.3.1. Value (US$ Mn) Forecast by Product Type 9.3.2. Y-o-Y Growth Comparison by Product Type 9.4. CIS & Russia Cancer Profiling Market Analysis by Indication 9.4.1. Value (US$ Mn) Forecast by Indication 9.4.2. Y-o-Y Growth Comparison by Indication 9.5. CIS & Russia Cancer Profiling Market Analysis by End User 9.5.1. Value (US$ Mn) Forecast by End User 9.5.2. Y-o-Y Growth Comparison by End User 9.6. Market Attractiveness Analysis 9.7. Heat Map Analysis 9.8. Impact Assessment of Market Forces 10. Japan Cancer Profiling Market Analysis and Forecast 10.1.Introduction 10.1.1. Japan Cancer Profiling Market Outlook 10.2.Japan Cancer Profiling Market Outlook 10.2.1. Market Value (US$ Mn) Forecast and Analysis 10.3.Japan Cancer Profiling Market Analysis by Product Type 10.3.1. Value (US$ Mn) Forecast by Product Type 10.3.2. Y-o-Y Growth Comparison by Product Type 10.4.Japan Cancer Profiling Market Analysis by Indication 10.4.1. Value (US$ Mn) Forecast by Indication 10.4.2. Y-o-Y Growth Comparison by Indication 10.5.Japan Cancer Profiling Market Analysis by End User 10.5.1. Value (US$ Mn) Forecast by End User 10.5.2. Y-o-Y Growth Comparison by End User 10.6.Market Attractiveness Analysis 10.7.Heat Map Analysis 10.8.Impact Assessment of Market Forces 11. APEJ Cancer Profiling Market Analysis and Forecast 11.1.Introduction 11.1.1. APEJ Cancer Profiling Market Outlook 11.2.APEJ Cancer Profiling Market Outlook 11.2.1. Market Value (US$ Mn) Forecast and Analysis 11.2.2. Country Wise Demand Assessment 11.2.2.1. Greater China Market Value Share 11.2.2.2. India Market Value Share 11.2.2.3. ASEAN Market Value Share 11.2.2.4. South Korea Market Value Share 11.2.2.5. ANZ Market Value Share 11.2.2.6. Rest of APEJ Market Value Share 11.3.APEJ Cancer Profiling Market Analysis by Product Type 11.3.1. Value (US$ Mn) Forecast by Product Type 11.3.2. Y-o-Y Growth Comparison by Product Type 11.4.APEJ Cancer Profiling Market Analysis by Indication 11.4.1. Value (US$ Mn) Forecast by Indication 11.4.2. Y-o-Y Growth Comparison by Indication 11.5.APEJ Cancer Profiling Market Analysis by End User 11.5.1. Value (US$ Mn) Forecast by End User 11.5.2. Y-o-Y Growth Comparison by End User 11.6.Market Attractiveness Analysis 11.7.Heat Map Analysis 11.8.Impact Assessment of Market Forces 12. MEA Cancer Profiling Market Analysis and Forecast 12.1.Introduction 12.1.1. MEA Cancer Profiling Market Outlook 12.2.MEA Cancer Profiling Market Outlook 12.2.1. Market Value (US$ Mn) Forecast and Analysis 12.2.2. Country Wise Demand Assessment 12.2.2.1. GCC Countries Market Value Share 12.2.2.2. South Africa Market Value Share 12.2.2.3. Turkey Market Value Share 12.2.2.4. Rest of MEA Market Value Share 12.3.MEA Cancer Profiling Market Analysis by Product Type 12.3.1. Value (US$ Mn) Forecast by Product Type 12.3.2. Y-o-Y Growth Comparison by Product Type 12.4.MEA Cancer Profiling Market Analysis by Indication 12.4.1. Value (US$ Mn) Forecast by Indication 12.4.2. Y-o-Y Growth Comparison by Indication 12.5.MEA Cancer Profiling Market Analysis by End User 12.5.1. Value (US$ Mn) Forecast by End User 12.5.2. Y-o-Y Growth Comparison by End User 12.6.Market Attractiveness Analysis 12.7.Heat Map Analysis 12.8.Impact Assessment of Market Forces 13. Global Cancer Profiling Market Value (US$ Mn) and Volume (‘000 tests) Analysis, By Tests Type, 2020 13.1.Introduction 13.2.North America Cancer Profiling Tests Value (US$ Mn) & Volume (‘000 tests) Analysis, 2020 13.2.1. Immunohistochemistry (IHC) 13.2.2. Fluorescence In situ Hybridization (FISH) 13.2.3. Quantitative Polymerase Chain Reaction (qPCR) 13.2.4. Next-Generation Sequencing (NGS) 13.2.5. Sanger Sequencing 13.2.6. Fragment Analysis 13.3.Latin America Cancer Profiling Tests Value (US$ Mn) & Volume (‘000 tests) Analysis, 2020 13.4.Europe Cancer Profiling Tests Value (US$ Mn) & Volume (‘000 tests) Analysis, 2020 13.5.CIS & Russia Cancer Profiling Tests Value (US$ Mn) & Volume (‘000 tests) Analysis, 2020 13.6.APEJ Cancer Profiling Tests Value (US$ Mn) & Volume (‘000 tests) Analysis, 2020 13.7.Japan Cancer Profiling Tests Value (US$ Mn) & Volume (‘000 tests) Analysis, 2020 13.8.MEA Cancer Profiling Tests Value (US$ Mn) & Volume (‘000 tests) Analysis, 2020 14. Competitive Assessment 14.1.Global Cancer Profiling Market Competition - a Dashboard View 14.2.Global Cancer Profiling Market Structure (2020) 15. Company Profiles 15.1.Qiagen N.V. 15.1.1. Geographical Footprint 15.1.2. Regional Revenue 15.1.3. Key Financials 15.1.4. SWOT Analysis 15.2.Roche Molecular Systems INC. 15.3.Abbott Laboratories 15.4.Siemens AG 15.5.Neogenomics Laboratories 15.6.Illumina, Inc. 15.7.HTG Molecular Diagnostic 15.8.PerkinElmer Inc. 15.9.Genomic Health INC. 15.10.Nanostring Technologies, Inc. 15.11.BioGenex 15.12.Thermo Fisher Scientific Inc. 15.13.Pacific Biosciences 15.14.Agilent Technologies, Inc. 16. Assumptions and Acronyms Used 17. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Region
Table 02: Global Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Product Type
Table 03: Global Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication
Table 04: Global Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By End User
Table 05: North America Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 06: North America Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Product Type
Table 07: North America Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication
Table 08: North America Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By End User
Table 09: Latin America Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 10: Latin America Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Product Type
Table 11: Latin America Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication
Table 12: Latin America Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By End User
Table 13: Europe Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 14: Europe Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Product Type
Table 15: Europe Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication
Table 16: Europe Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By End User
Table 17: CIS & Russia Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Product Type
Table 18: CIS & Russia Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication
Table 19: CIS & Russia Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By End User
Table 20: Japan Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Product Type
Table 21: Japan Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication
Table 22: Japan Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By End User
Table 23: APEJ Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 24: APEJ Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Product Type
Table 25: APEJ Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication
Table 26: APEJ Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By End User
Table 27: MEA Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 28: MEA Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Product Type
Table 29: MEA Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication
Table 30: MEA Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By End User
Table 31: Global Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Test Type
Table 32: Global Cancer Profiling Market Volume (000’Units) Analysis 2016-2020 and Forecast 2021-2031, By Test Type
Table 33: North America Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Test Type
Table 34: North America Cancer Profiling Market Volume (000’Units) Analysis 2016-2020 and Forecast 2021-2031, By Test Type
Table 35: Latin America Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Test Type
Table 36: Latin America Cancer Profiling Market Volume (000’Units) Analysis 2016-2020 and Forecast 2021-2031, By Test Type
Table 37: Europe Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Test Type
Table 38: Europe Cancer Profiling Market Volume (000’Units) Analysis 2016-2020 and Forecast 2021-2031, By Test Type
Table 39: CIS & Russia Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Test Type
Table 40: CIS & Russia Cancer Profiling Market Volume (000’Units) Analysis 2016-2020 and Forecast 2021-2031, By Test Type
Table 41: Japan Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Test Type
Table 42: Japan Cancer Profiling Market Volume (000’Units) Analysis 2016-2020 and Forecast 2021-2031, By Test Type
Table 43: APEJ Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Test Type
Table 44: APEJ Cancer Profiling Market Volume (000’Units) Analysis 2016-2020 and Forecast 2021-2031, By Test Type
Table 45: MEA Cancer Profiling Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Test Type
Table 46: MEA Cancer Profiling Market Volume (000’Units) Analysis 2016-2020 and Forecast 2021-2031, By Test Type
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Cancer Profiling Market Revenue Share by Product Type, 2021E & 2031F
Figure 02: Cancer Profiling Market Revenue Share by Indication , 2021E & 2031F
Figure 03: Cancer Profiling Market Revenue Share by end users , 2021E & 2031F
Figure 04: Cancer Profiling Market Revenue Share by Region, 2021E & 2031F
Figure 05: Wheel Of Fortune
Figure 06: IHC Test Pricing Analysis (US$) By Region, 2020 (Per Unit)
Figure 07: FISH Pricing Analysis (US$) By Region, 2020 (Per Unit)
Figure 08: qPCR Test Pricing Analysis (US$) By Region, 2020 (Per Unit)
Figure 09: NGS Pricing Analysis (US$) By Region, 2020 (Per Unit)
Figure 10: Fragment Analysis Test Pricing Analysis (US$) By Region, 2020 (Per Unit)
Figure 11: Sanger Sequencing Test Pricing Analysis (US$) By Region, 2020 (Per Unit)
Figure 12: Global Cancer Profiling Market, by Indication (2020)
Figure 13: Global Cancer Profiling Market, by Country (2020)
Figure 14: Global Cancer Profiling Market, by End User (2020)
Figure 15: Global Cancer Profiling Market Size (US$ Mn), 2016–2020
Figure 16: Global Cancer Profiling Market Size (US$) & Y-o-Y Growth (%), 2021–2031
Figure 17: North America Cancer Profiling Market Size (US$ Mn) Analysis, 2016–2020
Figure 18: North America Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031
Figure 19: Latin America Cancer Profiling Size (US$ Mn) Analysis, 2016–2020
Figure 20: Latin America Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031
Figure 21: Europe Cancer Profiling Market Size (US$ Mn) Analysis, 2016–2020
Figure 22: Europe Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031
Figure 23: CIS & Russia Cancer Profiling Size (US$ Mn) Analysis, 2016–2020
Figure 24: CIS & Russia Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031
Figure 25: Japan Cancer Profiling Market Size (US$ Mn) Analysis, 2016–2020
Figure 26: Japan Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031
Figure 27: APEJ Cancer Profiling Size (US$ Mn) Analysis, 2016–2020
Figure 28: APEJ Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031
Figure 29: MEA Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031
Figure 30: MEA Cancer Profiling Market Size (US$ Mn) Analysis, 2016–2020
Figure 31: Global Cancer Profiling Market Size (US$ Mn) Analysis, 2016–2020, by Instruments
Figure 32: Global Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031, by Instruments
Figure 33: Global Cancer Profiling Size (US$ Mn) Analysis, 2016–2020, by Consumables
Figure 34: Global Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031, by Consumables
Figure 35: North America Cancer Profiling Market Attractiveness Analysis, By Country
Figure 36: Global Cancer Profiling Market Attractiveness Analysis, By Product Type
Figure 37: Global Cancer Profiling Market Attractiveness Analysis, By Indication
Figure 38: North America Cancer Profiling Market Attractiveness Analysis, By End User
Figure 39: North America Cancer Profiling Market, by Product Type (2020)
Figure 40: North America Cancer Profiling Market, Snapshot
Figure 41: North America Cancer Profiling Market, by Indication (2020)
Figure 42: North America Cancer Profiling Market, by Country (2020)
Figure 43: North America Cancer Profiling Market, by End User (2020)
Figure 44: North America Cancer Profiling Market Size (US$ Mn), 2016–2020
Figure 45: North America Cancer Profiling Market Size (US$) & Y-o-Y Growth (%), 2021–2031
Figure 46: U.S. Cancer Profiling Market Size (US$ Mn) Analysis, 2016–2020
Figure 47: U.S. Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031
Figure 48: Canada Cancer Profiling Size (US$ Mn) Analysis, 2016–2020
Figure 49: Canada Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031
Figure 50: North America Cancer Profiling Market Size (US$ Mn) Analysis, 2016–2020, by Instruments
Figure 51: North America Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031, by Instruments
Figure 52: North America Cancer Profiling Size (US$ Mn) Analysis, 2016–2020, by Consumables
Figure 53: North America Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031, by Consumables
Figure 54: North America Cancer Profiling Market Attractiveness Analysis, By Country
Figure 55: North America Cancer Profiling Market Attractiveness Analysis, By Product Type
Figure 56: North America Cancer Profiling Market Attractiveness Analysis, By Indication
Figure 57: North America Cancer Profiling Market Attractiveness Analysis, By End User
Figure 58: Latin America Cancer Profiling Market, by Product Type (2020)
Figure 59: Latin America Cancer Profiling Market, Snapshot
Figure 60: Latin America Cancer Profiling Market, by Indication (2020)
Figure 61: Latin America Cancer Profiling Market, by Country (2020)
Figure 62: Latin America Cancer Profiling Market, by End User (2020)
Figure 63: Latin America Cancer Profiling Market Size (US$ Mn), 2016–2020
Figure 64: Latin America Cancer Profiling Market Size (US$) & Y-o-Y Growth (%), 2021–2031
Figure 65: Brazil Cancer Profiling Market Size (US$ Mn) Analysis, 2016–2020
Figure 66: Brazil Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031
Figure 67: Mexico Cancer Profiling Size (US$ Mn) Analysis, 2016–2020
Figure 68: Mexico Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031
Figure 69: Rest of Latin America Cancer Profiling Market Size (US$ Mn) Analysis, 2016–2020
Figure 70: Rest of Latin America Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031
Figure 71: Latin America Cancer Profiling Market Size (US$ Mn) Analysis, 2016–2020, by Instruments
Figure 72: Latin America Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031, by Instruments
Figure 73: Latin America Cancer Profiling Size (US$ Mn) Analysis, 2016–2020, by Consumables
Figure 74: Latin America Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031, by Consumables
Figure 75: Latin America Cancer Profiling Market Attractiveness Analysis, By Country
Figure 76: Latin America Cancer Profiling Market Attractiveness Analysis, By Product Type
Figure 77: Latin America Cancer Profiling Market Attractiveness Analysis, By Indication
Figure 78: Latin America Cancer Profiling Market Attractiveness Analysis, By End User
Figure 79: Europe Cancer Profiling Market, by Product Type (2020)
Figure 80: Europe Cancer Profiling Market, Snapshot
Figure 81: Europe Cancer Profiling Market, by Indication (2020)
Figure 82: Europe Cancer Profiling Market, by Country (2020)
Figure 83: Europe Cancer Profiling Market, by End User (2020)
Figure 84: Europe Cancer Profiling Market Size (US$ Mn), 2016–2020
Figure 85: Europe Cancer Profiling Market Size (US$) & Y-o-Y Growth (%), 2021–2031
Figure 86: EU-4 Cancer Profiling Market Size (US$ Mn) Analysis, 2016–2020
Figure 87: EU-4 Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031
Figure 88: U.K. Cancer Profiling Size (US$ Mn) Analysis, 2016–2020
Figure 89: U.K. Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031
Figure 90: Benelux Cancer Profiling Market Size (US$ Mn) Analysis, 2016–2020
Figure 91: Benelux Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031
Figure 92: Nordic Cancer Profiling Size (US$ Mn) Analysis, 2016–2020
Figure 93: Nordic Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031
Figure 94: Rest of Europe Cancer Profiling Market Size (US$ Mn) Analysis, 2016–2020
Figure 95: Rest of Europe Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031
Figure 96: Europe Cancer Profiling Market Size (US$ Mn) Analysis, 2016–2020, by Instruments
Figure 97: Europe Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031, by Instruments
Figure 98: Europe Cancer Profiling Size (US$ Mn) Analysis, 2016–2020, by Consumables
Figure 99: Europe Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031, by Consumables
Figure 100: Europe Cancer Profiling Market Attractiveness Analysis, By Country
Figure 101: Europe Cancer Profiling Market Attractiveness Analysis, By Product Type
Figure 102: Europe Cancer Profiling Market Attractiveness Analysis, By Indication
Figure 103: Europe Cancer Profiling Market Attractiveness Analysis, By End User
Figure 104: CIS & Russia Cancer Profiling Market, by Product Type (2020)
Figure 105: CIS & Russia Cancer Profiling Market, Snapshot
Figure 106: CIS & Russia Cancer Profiling Market, by Indication (2020)
Figure 107: CIS & Russia Cancer Profiling Market, by End User (2020)
Figure 108: CIS & Russia Cancer Profiling Market Size (US$ Mn), 2016–2020
Figure 109: CIS & Russia Cancer Profiling Market Size (US$) & Y-o-Y Growth (%), 2021–2031
Figure 110: CIS & Russia Cancer Profiling Market Size (US$ Mn) Analysis, 2016–2020, by Instruments
Figure 111: CIS & Russia Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031, by Instruments
Figure 112: CIS & Russia Cancer Profiling Size (US$ Mn) Analysis, 2016–2020, by Consumables
Figure 113: CIS & Russia Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031, by Consumables
Figure 114: CIS & Russia Cancer Profiling Market Attractiveness Analysis, By Product Type
Figure 115: CIS & Russia Cancer Profiling Market Attractiveness Analysis, By Indication
Figure 116: CIS & Russia Cancer Profiling Market Attractiveness Analysis, By End User
Figure 117: Japan Cancer Profiling Market, by Product Type (2020)
Figure 118: Japan Cancer Profiling Market, Snapshot
Figure 119: Japan Cancer Profiling Market, by Indication (2020)
Figure 120: Japan Cancer Profiling Market, by End User (2020)
Figure 121: Japan Cancer Profiling Market Size (US$ Mn), 2016–2020
Figure 122: Japan Cancer Profiling Market Size (US$) & Y-o-Y Growth (%), 2021–2031
Figure 123: Japan Cancer Profiling Market Size (US$ Mn) Analysis, 2016–2020, by Instruments
Figure 124: Japan Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031, by Instruments
Figure 125: Japan Cancer Profiling Size (US$ Mn) Analysis, 2016–2020, by Consumables
Figure 126: Japan Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031, by Consumables
Figure 127: Japan Cancer Profiling Market Attractiveness Analysis, By Product Type
Figure 128: Japan Cancer Profiling Market Attractiveness Analysis, By Indication
Figure 129: Japan Cancer Profiling Market Attractiveness Analysis, By End User
Figure 130: APEJ Cancer Profiling Market, by Product Type (2020)
Figure 131: APEJ Cancer Profiling Market, Snapshot
Figure 132: APEJ Cancer Profiling Market, by Indication (2020)
Figure 133: APEJ Cancer Profiling Market, by Country (2020)
Figure 134: APEJ Cancer Profiling Market, by End User (2020)
Figure 135: APEJ Cancer Profiling Market Size (US$ Mn), 2016–2020
Figure 136: APEJ Cancer Profiling Market Size (US$) & Y-o-Y Growth (%), 2021–2031
Figure 137: Greater China Cancer Profiling Market Size (US$ Mn) Analysis, 2016–2020
Figure 138: Greater China Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031
Figure 139: India Cancer Profiling Size (US$ Mn) Analysis, 2016–2020
Figure 140: India Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031
Figure 141: ASEAN Cancer Profiling Market Size (US$ Mn) Analysis, 2016–2020
Figure 142: ASEAN Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031
Figure 143: South Korea Cancer Profiling Size (US$ Mn) Analysis, 2016–2020
Figure 144: South Korea Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031
Figure 145: Australia & New Zealand Cancer Profiling Market Size (US$ Mn) Analysis, 2016–2020
Figure 146: Australia & New Zealand Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031
Figure 147: Rest of APEJ Cancer Profiling Size (US$ Mn) Analysis, 2016–2020
Figure 148: Rest of APEJ Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031
Figure 149: APEJ Cancer Profiling Market Size (US$ Mn) Analysis, 2016–2020, by Instruments
Figure 150: APEJ Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031, by Instruments
Figure 151: APEJ Cancer Profiling Size (US$ Mn) Analysis, 2016–2020, by Consumables
Figure 152: APEJ Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031, by Consumables
Figure 153: APEJ Cancer Profiling Market Attractiveness Analysis, By Country
Figure 154: APEJ Cancer Profiling Market Attractiveness Analysis, By Product Type
Figure 155: APEJ Cancer Profiling Market Attractiveness Analysis, By Indication
Figure 156: APEJ Cancer Profiling Market Attractiveness Analysis, By End User
Figure 157: MEA Cancer Profiling Market, by Product Type (2020)
Figure 158: MEA Cancer Profiling Market, Snapshot
Figure 159: MEA Cancer Profiling Market, by Indication (2020)
Figure 160: MEA Cancer Profiling Market, by Country (2020)
Figure 161: MEA Cancer Profiling Market, by End User (2020)
Figure 162: MEA Cancer Profiling Market Size (US$ Mn), 2016–2020
Figure 163: MEA Cancer Profiling Market Size (US$) & Y-o-Y Growth (%), 2021–2031
Figure 164: GCC Cancer Profiling Market Size (US$ Mn) Analysis, 2016–2020
Figure 165: GCC Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031
Figure 166: South Africa Cancer Profiling Size (US$ Mn) Analysis, 2016–2020
Figure 167: South Africa Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031
Figure 168: Turkey Cancer Profiling Market Size (US$ Mn) Analysis, 2016–2020
Figure 169: Turkey Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031
Figure 170: Rest of MEA Cancer Profiling Size (US$ Mn) Analysis, 2016–2020
Figure 171: Rest of MEA Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031
Figure 172: MEA Cancer Profiling Market Size (US$ Mn) Analysis, 2016–2020, by Instruments
Figure 173: MEA Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031, by Instruments
Figure 174: MEA Cancer Profiling Size (US$ Mn) Analysis, 2016–2020, by Consumables
Figure 175: MEA Cancer Profiling Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031, by Consumables
Figure 176: MEA Cancer Profiling Market Attractiveness Analysis, By Country
Figure 177: MEA Cancer Profiling Market Attractiveness Analysis, By Product Type
Figure 178: MEA Cancer Profiling Market Attractiveness Analysis, By Indication
Figure 179: MEA Cancer Profiling Market Attractiveness Analysis, By End User
Figure 180: Global Cancer Profiling Market, by Test Type (2020)
Figure 181: Global Cancer Profiling Market, By Test Type, Snapshot
Figure 182: Global Cancer Profiling Market Size (US$ Mn), 2016–2020, By Test Type
Figure 183: Global Cancer Profiling Market Size (US$) & Y-o-Y Growth (%), 2021–2031, By Test Type
Figure 184: North America Cancer Profiling Market, by Test Type (2020)
Figure 185: North America Cancer Profiling Market, By Test Type, Snapshot
Figure 186: North America Cancer Profiling Market Size (US$ Mn), 2016–2020, By Test Type
Figure 187: North America Cancer Profiling Market Size (US$) & Y-o-Y Growth (%), 2021–2031, By Test Type
Figure 188: Latin America Cancer Profiling Market, by Test Type (2020)
Figure 189: Latin America Cancer Profiling Market, By Test Type, Snapshot
Figure 190: Latin America Cancer Profiling Market Size (US$ Mn), 2016–2020, By Test Type
Figure 191: Latin America Cancer Profiling Market Size (US$) & Y-o-Y Growth (%), 2021–2031, By Test Type
Figure 192: Europe Cancer Profiling Market, by Test Type (2020)
Figure 193: Europe Cancer Profiling Market, By Test Type, Snapshot
Figure 194: Europe Cancer Profiling Market Size (US$ Mn), 2016–2020, By Test Type
Figure 195: Europe Cancer Profiling Market Size (US$) & Y-o-Y Growth (%), 2021–2031, By Test Type
Figure 196: CIS & Russia Cancer Profiling Market, by Test Type (2020)
Figure 197: CIS & Russia Cancer Profiling Market, By Test Type, Snapshot
Figure 198: CIS & Russia Cancer Profiling Market Size (US$ Mn), 2016–2020, By Test Type
Figure 199: CIS & Russia Cancer Profiling Market Size (US$) & Y-o-Y Growth (%), 2021–2031, By Test Type
Figure 200: Japan Cancer Profiling Market, by Test Type (2020)
Figure 201: Japan Cancer Profiling Market, By Test Type, Snapshot
Figure 202: Japan Cancer Profiling Market Size (US$ Mn), 2016–2020, By Test Type
Figure 203: Japan Cancer Profiling Market Size (US$) & Y-o-Y Growth (%), 2021–2031, By Test Type
Figure 204: APEJ Cancer Profiling Market, by Test Type (2020)
Figure 205: APEJ Cancer Profiling Market, By Test Type, Snapshot
Figure 206: APEJ Cancer Profiling Market Size (US$ Mn), 2016–2020, By Test Type
Figure 207: APEJ Cancer Profiling Market Size (US$) & Y-o-Y Growth (%), 2021–2031, By Test Type
Figure 208: MEA Cancer Profiling Market, by Test Type (2020)
Figure 209: MEA Cancer Profiling Market, By Test Type, Snapshot
Figure 210: MEA Cancer Profiling Market Size (US$ Mn), 2016–2020, By Test Type
Figure 211: MEA Cancer Profiling Market Size (US$) & Y-o-Y Growth (%), 2021–2031, By Test Type
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How will the global cancer profiling market expand through 2031?
The global market is expected to witness credible gains through 2031, primarily driven by burgeoning research in advancing precision-based treatment and incorporation of technological advancements
Which regions are likely to be most lucrative for cancer profiling?
According to Fact.MR, suppliers and manufacturers are increasingly targeting emerging economies across Asia Pacific. Maximum growth opportunities are visible across India, as it possesses the world’s largest population base.
Why is profiling demand for non-small cell lung cancer diagnosis aggrandizing?
Testing for detecting possible cases of non-small cell lung cancer (NSCLC) is acquiring momentum, as the prevalence rate is expected to compound over the coming years. Various respiratory disorders arising out of sedentary habits such as smoking are le
Which prominent players operate in the global cancer profiling landscape?
Fact.MR’s report has profiled the following players in its study: F. Hoffmann La Roche Ltd, Illumina Inc, QIAGEN, Thermo Fisher Scientific Inc, Abbott, Nanostring Technologies Inc, Siemens AG, HTG Molecular Diagnostics, Inc, Perkin Elmer Inc
Cancer Profiling Market